Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07278310 · ClinicalTrials.gov registry record · NA

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

A NA study, sponsored by MiRus.

Recruiting
Registry status
NA
Development phase
1,025
Enrollment target

NCT07278310: Recruiting NA study, sponsored by MiRus.

NCT07278310 is a NA study that is actively recruiting participants, run by MiRus. The registered enrollment target is 1,025 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07278310, a NA study, is actively recruiting participants, sponsored by MiRus.

RECRUITING
Registry status
NA
Development phase
1,025 participants
Enrollment target

Study Summary

To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis.

Primary Outcome

The primary endpoint is the composite of all-cause mortality, all stroke, and cardiovascular rehospitalization (valve-related or procedure-related per VARC-3) at 1 year.

Interventions

  • DEVICE TAVR Device
  • DEVICE Siegel TAVR Device

Trial Details

FieldValue
Enrollment Target 1,025 participants
Start Date 2026-04
Est. Completion 2028-04
Phase NA
MiRus

2 total trials

What NCT07278310 shows while recruiting

NCT07278310 is an interventional study that assigns participants to a tested intervention. Its 1,025 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower).

The record links to 0 conditions, and to 2 interventions - of which TAVR Device is the first listed.

NCT07278310 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07278310 about?

NCT07278310 is a clinical study titled "STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)". To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis.

What is the current status of trial NCT07278310?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,025 participants. The study started on 2026-04. Estimated completion is 2028-04.

What interventions are being tested in trial NCT07278310?

The interventions under investigation include: TAVR Device (DEVICE), Siegel TAVR Device (DEVICE).

Who is sponsoring clinical trial NCT07278310?

This trial is sponsored by MiRus, which has 2 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07278310's enrollment target sits among peer trials

1,025 104th of 2000 higher than 1,896 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02200276 · 1,025 participants · NA

    Influenza Immunization in Adults Over Age 75

  • NCT02296450 · 1,025 participants

    Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

  • NCT06888011 · 1,024 participants · NA

    iAmHealthy Clinical Practice Guideline (CPG)

  • NCT07216703 · 1,023 participants · Phase 3

    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07278310, the US trial registry maintained by the National Library of Medicine. NCT07278310 (large enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.